Bristol Serzone Hepatic Risk Suggests Need For Second-Line Use, Revised Labeling Says

Approval of revised nefazodone labeling roughly coincides with the timing of Bristol's decision to remove Serzone from the market for commercial reasons. Impact of labeling revision will therefore fall on marketers of generic nefazodone.